Mavorixafor
As of the edition of 20 October 2026, Mavorixafor is a small molecule: marketed, first approved in 2024 (US); acts on CXCR4; US protection ends in 2031.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2026
- Kind
- Small molecule
- Brand name
- Xolremdi
- First approved
- 26 April 2024 (US)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Norgine B.V.; 2 holders in all
- Registered trials
- 15, 2 stopped early
- Disease areas
- Cancer; Immune system; Urinary and reproductive; Blood and lymph; Infections; Digestive system
US protection
US protection ends in 2031.
The last listed US exclusivity ends in 2031. The application that gives this date is held by X4 Pharmaceuticals.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Mavorixafor.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CXCR4 | C-X-C chemokine receptor type 4 | P61073 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 7 | 6 | 0 | 1 |
| Phase 2 | 6 | 4 | 0 | 1 |
| Phase 3 | 2 | 1 | 1 | 0 |
| All trials | 15 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| X4 Pharmaceuticals | Originator and Lead sponsor of trials | 2016 to now |